Home Biomarkers Anti HCV

Anti HCV

Hepatitis Biomarker

Sample Needed

Collection Type: Blood

Body System

Related System: Hepatitis

Overview

Anti‑HCV (antibodies to hepatitis C virus) is an immunologic test that detects antibodies produced in response to HCV infection. The assay measures whether the immune system has seen HCV proteins, indicating past or current exposure; it does not directly measure virus (HCV RNA). It is used to screen for hepatitis C in people with risk factors or symptoms such as jaundice, fatigue, dark urine, abdominal pain, or unexplained elevated liver enzymes. Positive rates vary by age/cohort and risk behaviors (higher in people who inject drugs, recipients of blood transfusions before 1992, and certain birth cohorts). Immunosuppressed patients and infants of infected mothers require special interpretation (false negatives or passive maternal antibodies).

People also test for

Test Preparation

No special preparation is required

Why Do I Need This Test

Profile: Hepatitis (HCV screening/diagnosis) - Symptoms prompting test: jaundice, fatigue, right‑upper‑quadrant pain, dark urine, unexplained elevated ALT/AST - Diagnoses/monitoring: detects past exposure; prompts confirmatory HCV RNA testing to diagnose active infection and guide treatment - Reasons for abnormal (reactive) result: prior or current HCV infection, vaccination is not relevant (no HCV vaccine) - Biological meaning: reactive = antibody formation to HCV; nonreactive = no detectable antibody or testing within window period - Behaviors/factors: IV drug use, blood transfusion before 1992, high‑risk sexual exposure, hemodialysis, occupational needle exposure - Family history: household/sexual contact with known HCV‑positive person indicates need for testing

Run our symptom checker to see if this test is right for you

Symptom Checker

Understanding Test Results

Non‑reactive (S/CO <1.0): no detectable anti‑HCV antibodies suggests no past exposure or testing during early window period; HCV RNA may still be positive in very early infection.
Reactive (S/CO ≥1.0): antibodies detected indicates exposure to HCV at some time.
Confirmatory testing with HCV RNA PCR is required to determine active infection (RNA positive current infection).
Strongly reactive/high signal ratios (often S/CO ≥3 or above depending on assay) increase likelihood of true positive.
False positives occur in low‑prevalence settings; false negatives occur in immunosuppressed patients or during the first 4–12 weeks after infection.
Antibodies can persist for years after successful treatment or spontaneous clearance.

Normal Range

Non‑reactive (Negative) OR S/CO 1.0 (index, unitless)

FAQs

Q: What is anti-HCV?

A: Anti‑HCV are antibodies produced in response to hepatitis C virus. An anti‑HCV test screens for past or current exposure but cannot distinguish resolved from active infection; a positive result requires confirmatory HCV RNA testing to detect ongoing viral replication. Antibodies usually appear 4–12 weeks after infection, so repeat testing or RNA testing may be needed following recent exposure.

Q: Is HCV a serious disease?

A: Hepatitis C virus (HCV) can be serious. While initial infection is often mild or asymptomatic, most cases become chronic and can cause long-term liver inflammation leading to fibrosis, cirrhosis, liver failure and increased risk of liver cancer. Effective, well-tolerated antiviral treatments can cure most people, so early testing and treatment greatly reduce the risk of severe complications.

Q: What is anti-HCV normal range?

A: Anti‑HCV (hepatitis C antibody) is reported as non‑reactive/negative in a normal result. Many labs use a signal/cutoff (S/CO) ratio: <1.0 non‑reactive (normal), ≥1.0 reactive (requires confirmation). A reactive antibody does not distinguish past from active infection; follow‑up HCV RNA testing is needed. Antibodies may take about 6–12 weeks after exposure to appear.

Q: Is HCV an STD?

A: Hepatitis C (HCV) is primarily a blood-borne infection, not usually classified as a sexually transmitted disease. Sexual transmission is possible but uncommon in monogamous heterosexual relationships; risk rises with multiple partners, HIV co-infection, rough sex, or other STIs. Major transmission routes are shared needles, unsterile medical procedures, and contaminated blood products; mother-to-child transmission is possible but uncommon.

Q: Is HCV negative good or bad?

A: HCV negative is generally good: it means no evidence of active hepatitis C infection. Interpretation depends on the test—HCV RNA negative indicates no current viral replication (often meaning cure after treatment), while an antibody negative result means no prior exposure. Antibody positive but RNA negative suggests past, resolved infection. If you have risk factors or symptoms, ask your clinician about repeat or confirmatory testing.

Q: How do you treat anti HCV positive?

A: If anti‑HCV antibody is positive, confirm active infection with HCV RNA testing. If RNA positive, stage liver disease (fibrosis), screen for HBV/HIV, and start direct‑acting antiviral therapy (usually 8–12 weeks) per specialist guidance. Avoid alcohol, vaccinate against hepatitis A/B if susceptible, monitor liver tests, and repeat HCV RNA 12 weeks after treatment to confirm cure (SVR12).